Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease
Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease
This was a randomized, single-blind, parallel, placebo-controlled clinical trial assessing
 the efficacy of neuronavigational TBS among patients with AD. Fourty late-onset AD were
 included in the study, all the patients were divided into TBS groups and drug treatment
 group. Drug intervention group AD patients with drug regimen (donepezil 5mg / d) and primary
 care guidance, once every three months follow-up. TBS group is treated with TBS (a course of
 treatment every 3 months); after completing 4 treatments/follow-ups a year, evaluate the
 changes in MoCA, other clinical symptoms and multi-domain cognition tests, and brain Changes
 in structure and function.
Inclusion Criteria:

 -  Subject diagnosed with early Alzheimer's disease or related diseases according to
 NINCDS-ACDRADA criteria.

 -  Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment
 or dementia

 -  CDR score ≤ 2

 -  Subject under treatment by IAChE for at least 3 Weeks.

 -  psychotropic treatments are tolerated if they were administered and unchanged for at
 least 3 months

 Exclusion Criteria:

 -  CDR > 2

 -  Any history or clinical signs of other severe psychiatric illnesses (like major
 depression,psychosis or obsessive compulsive disorder).

 - Page 5 of 6 [DRAFT] -

 -  History of head injury,stroke,or other neurologic disease.

 -  Organic brain defects on T1 or T2 images.

 -  History of seizures or unexplained loss of consciousness.

 -  Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.

 -  Family history of medication refractory epilepsy.

 -  History of substance abuse within the last 6 months.